CEA stands as a highly researched and confirmed serum indicator of non-small cell lung cancer (NSCLC) patients, beneficial in diagnosing, predicting outcomes, and evaluating treatments, especially in individuals with mutations in the epidermal growth factor receptor (EGFR) [45]. This evidence concerns the gene CEACAM5 and non-small cell lung carcinoma.